Current Pharmaceutical BiotechnologyCurrent Pharmaceutical BiotechnologyCurrent Pharmaceutical Biotechnology1389-20101873-4316Bentham Science64450410.2174/0113892010261502231102040149BiotechnologyResearch ArticleSystematic Review on Herbal Preparations for Controlling Visceral Hypersensitivity in Functional Gastrointestinal DisordersLashgariNaser-Aldininfo@benthamscience.netMomeni RoudsariNazanininfo@benthamscience.netMomtazSaeidehinfo@benthamscience.netNiazi ShahrakiFaezehinfo@benthamscience.netZandiNadiainfo@benthamscience.netPazokiBenyamininfo@benthamscience.netFarzaeiMohammadinfo@benthamscience.netGhasemiMehdiinfo@benthamscience.netAbdollahiMohammadinfo@benthamscience.netAbdolghaffariAmir Hosseininfo@benthamscience.netDepartment of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University Pharmaceutical Sciences BranchMedicinal Plants Research Center, Institute of Medicinal Plants, ACECRDepartment of Pharmacology,, Tehran University of Medical SciencesDepartment of Pharmacology, Tehran University of Medical SciencesPharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical SciencesDepartment of Neurology, University of Massachusetts School of MedicineToxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), and Faculty of Pharmacy, Tehran University of Medical SciencesDepartment of Toxicology & Pharmacology, Faculty of Pharmacy,, Islamic Azad University Pharmaceutical Sciences Branch0107202425131632165007012025Copyright ©; 2024, Bentham Science Publishers2024Bentham Science Publishershttps://journals.eco-vector.com/1389-2010/article/view/644504

Background:Visceral hypersensitivity (VH) is an overreaction of the gastrointestinal (GI) tract to various stimuli and is characterized by hyperalgesia and/or allodynia. VH contributes to the etiology of many GI dysfunctions, particularly irritable bowel syndrome (IBS). Although the exact mechanisms underlying VH are yet to be found, inflammation and oxidative stress, psychosocial factors, and sensorimotor alterations may play significant roles in it.

Objective:In this review, we provide an overview of VH and its pathophysiological function in GI disorders. Adverse effects of synthetic drugs may make herbal agents a good candidate for pain management. Therefore, in this review, we will discuss the efficacy of herbal agents in the management of VH with a focus on their anti-inflammatory and antioxidant potentials.

Methods:Data were extracted from clinical and animal studies published in English between 2004 and June, 2020, which were collected from PubMed, Google Scholar, Scopus, and Cochrane Library.

Results:Overall, Radix, Melissia, Glycyrrhizae, Mentha, and Liquorice were the most efficient herbals for VH management in IBS and dyspepsia, predominantly through modulation of the mRNA expression of transient receptor potential vanilloid type-1 (TRPV1) and suppression of 5- hydroxytryptamine 3 (5-HT3) or the serotonin receptors.

Conclusion:Considering the positive effects of herbal formulations in VH management, further research on novel herbal and/or herbal/chemical preparations is warranted.

Visceral sensationfunctional dyspepsianon-erosive reflux disease (NERD)gastrointestinal diseasesIrritable Bowel Syndrome (IBS)herbal medicines.Farzaei, M.H.; Bahramsoltani, R.; Abdollahi, M.; Rahimi, R. The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments. J. Neurogastroenterol. Motil., 2016, 22(4), 558-574. doi: 10.5056/jnm16001 PMID: 27431236Greenwood-van meerveld, Importance of 5-hydroxytryptamine receptors on intestinal afferents in the regulation of visceral sensitivity. Neurogastroenterol. Motil., 2007, 19(s2)(Suppl. 2), 13-18. doi: 10.1111/j.1365-2982.2007.00964.x PMID: 17620083Yam, M.; Loh, Y.; Tan, C.; Khadijah Adam, S.; Abdul Manan, N.; Basir, R. General pathways of pain sensation and the major neurotransmitters involved in pain regulation. Int. J. Mol. Sci., 2018, 19(8), 2164. doi: 10.3390/ijms19082164 PMID: 30042373Feng, B.; La, J.H.; Schwartz, E.S.; Gebhart, G.F. Irritable Bowel Syndrome: Methods, Mechanisms, and Pathophysiology. Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol., 2012, 302(10), G1085-G1098. doi: 10.1152/ajpgi.00542.2011 PMID: 22403791Akhtar, M.S.; Aslam, M. Anthelmintic efficacies of total alkaloids and glycosides isolated from Punica granatum fruit-rind (anar); Pakistan J. Agricul. Sci, 1988.Liu, S.; Hagiwara, S.I.; Bhargava, A. Early‐life adversity, epigenetics, and visceral hypersensitivity. Neurogastroenterol. Motil., 2017, 29(9), e13170. doi: 10.1111/nmo.13170 PMID: 28782197Holzer, P.; Farzi, A.; Hassan, A.M.; Zenz, G.; Jačan, A.; Reichmann, F. Visceral inflammation and immune activation stress the brain. Front. Immunol., 2017, 8, 1613. doi: 10.3389/fimmu.2017.01613 PMID: 29213271Deiteren A.; de Wit, A.; van der Linden, L.; De Man, JG.; Pelckmans, P.A.; De Winter BY Irritable bowel syndrome and visceral hypersensitivity: risk factors and pathophysiological mechanisms. Acta Gastroenterol. Belg., 2016, 79(1), 29-38.Zhou, Q.; Verne, G.N. New insights into visceral hypersensitivity—clinical implications in IBS. Nat. Rev. Gastroenterol. Hepatol., 2011, 8(6), 349-355. doi: 10.1038/nrgastro.2011.83 PMID: 21643039Rexwinkel, R.; Zeevenhooven, J.; van Etten-Jamaludin, F.S.; Benninga, M.A.; Tabbers, M.M. Side effects associated with pharmacotherapy for pediatric irritable bowel syndrome and functional abdominal pain – not otherwise specified: a systematic review. Expert Opin. Drug Saf., 2019, 18(2), 111-125. doi: 10.1080/14740338.2019.1574295 PMID: 30676113Domagała-Rodacka, R.; Cibor, D.; Szczeklik, K.; Rodacki, T.; Mach, T.; Owczarek, D. Gastrointestinal tract as a side-effect target of medications. Przegl. Lek., 2016, 73(9), 652-658. PMID: 29688675Nyambe, M.; Koekemoer, T.; van de Venter, M.; Goosen, E.; Beukes, D. In vitro evaluation of the phytopharmacological potential of Sargassum incisifolium for the treatment of inflammatory bowel diseases. Medicines (Basel), 2019, 6(2), 49. doi: 10.3390/medicines6020049 PMID: 30959861Qu, L.; Liu, Q.; Zhang, Q.; Tuo, X.; Fan, D.; Deng, J.; Yang, H. Kiwifruit seed oil prevents obesity by regulating inflammation, thermogenesis, and gut microbiota in high-fat diet-induced obese C57BL/6 mice. Food Chem. Toxicol., 2019, 125, 85-94. doi: 10.1016/j.fct.2018.12.046 PMID: 30597221Cavalcante Silva, J; Grasseli, E; Canesi, L; Palombo, D; Abdalla, D. P310 A new dual-PPAR agonist (GQ-11), prevents ischemiareperfusion damage in rats after supraceliac aorta clamping. Eur Heart J-Cardiovas Imag, 2019, 20(Supplement_3), jez148.038.Stine, R.R.; Sakers, A.P.; TeSlaa, T.; Kissig, M.; Stine, Z.E.; Kwon, C.W.; Cheng, L.; Lim, H.W.; Kaestner, K.H.; Rabinowitz, J.D.; Seale, P. PRDM16 maintains homeostasis of the intestinal epithelium by controlling region-specific metabolism. Cell Stem Cell, 2019, 25(6), 830-845.e8. doi: 10.1016/j.stem.2019.08.017 PMID: 31564549Delvaux, M. Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome. Gut, 2002, 51(Suppl 1)(Suppl. 1), i67-i71. doi: 10.1136/gut.51.suppl_1.i67 PMID: 12077070Hockley, J.R.F.; Boundouki, G.; Cibert-Goton, V.; McGuire, C.; Yip, P.K.; Chan, C.; Tranter, M.; Wood, J.N.; Nassar, M.A.; Blackshaw, A.L.; Aziz, Q.; Michael, G.J.; Baker, M.D.; Winchester, W.J.; Knowles, C.H.; Bulmer, D.C. Multiple roles for NaV1.9 in the activation of visceral afferents by noxious inflammatory, mechanical, and human disease–derived stimuli. Pain, 2014, 155(10), 1962-1975. doi: 10.1016/j.pain.2014.06.015 PMID: 24972070Kanazawa, M.; Hongo, M.; Fukudo, S. Visceral hypersensitivity in irritable bowel syndrome. J. Gastroenterol. Hepatol., 2011, 26(s3)(Suppl. 3), 119-121. doi: 10.1111/j.1440-1746.2011.06640.x PMID: 21443723Sarnelli, G.; Vandenberghe, J.; Tack, J. Visceral hypersensitivity in functional disorders of the upper gastrointestinal tract. Dig. Liver Dis., 2004, 36(6), 371-376. doi: 10.1016/S1590-8658(04)00082-9 PMID: 15248374Schumacher, M.A. Transient receptor potential channels in pain and inflammation: therapeutic opportunities. Pain Pract., 2010, 10(3), 185-200. doi: 10.1111/j.1533-2500.2010.00358.x PMID: 20230457Farmer, A.D.; Aziz, Q. Gut pain & visceral hypersensitivity. Br. J. Pain, 2013, 7(1), 39-47. doi: 10.1177/2049463713479229 PMID: 26516496Keohane, J.; Quigley, E.M.M. Functional dyspepsia: The role of visceral hypersensitivity in its pathogenesis. World J. Gastroenterol., 2006, 12(17), 2672-2676. doi: 10.3748/wjg.v12.i17.2672 PMID: 16718751Keszthelyi, D.; Troost, F.J.; Masclee, A.A. Irritable Bowel Syndrome: Methods, Mechanisms, and Pathophysiology. Methods to assess visceral hypersensitivity in irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol., 2012, 303(2), G141-G154. doi: 10.1152/ajpgi.00060.2012 PMID: 22595988Spiller, R.; Lam, C. The shifting interface between IBS and IBD. Curr. Opin. Pharmacol., 2011, 11(6), 586-592. doi: 10.1016/j.coph.2011.09.009 PMID: 22000604Villani, A.C.; Lemire, M.; Thabane, M.; Belisle, A.; Geneau, G.; Garg, A.X.; Clark, W.F.; Moayyedi, P.; Collins, S.M.; Franchimont, D.; Marshall, J.K. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology, 2010, 138(4), 1502-1513. doi: 10.1053/j.gastro.2009.12.049 PMID: 20044998Klooker, T.K.; Braak, B.; Koopman, K.E.; Welting, O.; Wouters, M.M.; van der Heide, S.; Schemann, M.; Bischoff, S.C.; van den Wijngaard, R.M.; Boeckxstaens, G.E. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut, 2010, 59(9), 1213-1221. doi: 10.1136/gut.2010.213108 PMID: 20650926Tsang, S.W.; Zhao, M.; Wu, J.; Sung, J.J.Y.; Bian, Z.X. Nerve growth factor‐mediated neuronal plasticity in spinal cord contributes to neonatal maternal separation‐induced visceral hypersensitivity in rats. Eur. J. Pain, 2012, 16(4), 463-472. doi: 10.1016/j.ejpain.2011.07.005 PMID: 22396076Russo, E.B. Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Cannabis Cannabinoid Res., 2016, 1(1), 154-165. doi: 10.1089/can.2016.0009 PMID: 28861491Mawe, G.M.; Coates, M.D.; Moses, P.L. Review article: intestinal serotonin signalling in irritable bowel syndrome. Aliment. Pharmacol. Ther., 2006, 23(8), 1067-1076. doi: 10.1111/j.1365-2036.2006.02858.x PMID: 16611266Kim, J.J.; Kim, N.; Choi, Y.J.; Kim, J.S.; Jung, H.C. Increased TRPV1 and PAR2 mRNA expression levels are associated only with the esophageal reflux symptoms, but not with the extraesophageal reflux symptoms. Medicine (Baltimore), 2016, 95(32), e4387. doi: 10.1097/MD.0000000000004387 PMID: 27512850Yoshida, N.; Kuroda, M.; Suzuki, T.; Kamada, K.; Uchiyama, K.; Handa, O.; Takagi, T.; Yoshikawa, T.; Kuramoto, H. Role of nociceptors/neuropeptides in the pathogenesis of visceral hypersensitivity of nonerosive reflux disease. Dig. Dis. Sci., 2013, 58(8), 2237-2243. doi: 10.1007/s10620-012-2337-7 PMID: 22899239Sarkar, S.; Hobson, A.R.; Furlong, P.L.; Woolf, C.J.; Thompson, D.G.; Aziz, Q. Central neural mechanisms mediating human visceral hypersensitivity. Am. J. Physiol. Gastrointest. Liver Physiol., 2001, 281(5), G1196-G1202. doi: 10.1152/ajpgi.2001.281.5.G1196 PMID: 11668028Tack, J.; Vanuytsel, T.; Pauwels, A. Established and emerging treatment options for functional heartburn and chest pain. Curr. Treat. Options Gastroenterol., 2016, 14(1), 19-27. doi: 10.1007/s11938-016-0081-3 PMID: 26825704Van Handel, D.; Fass, R. The pathophysiology of non-cardiac chest pain. J. Gastroenterol. Hepatol., 2005, 20(s3)(Suppl.), S6-S13. doi: 10.1111/j.1440-1746.2005.04165.x PMID: 16359347Lee, J.Y.; Kim, N.; Park, J.H.; Nam, R.H.; Lee, S.M.; Song, C.H.; Kim, G.; Na, H.Y.; Choi, Y.J.; Kim, J.J.; Lee, D.H. Expression of neurotrophic factors, tight junction proteins, and cytokines according to the irritable bowel syndrome subtype and sex. J. Neurogastroenterol. Motil., 2020, 26(1), 106-116. doi: 10.5056/jnm19099 PMID: 31623029Naveed, M.; Hejazi, V.; Abbas, M.; Kamboh, A.A.; Khan, G.J.; Shumzaid, M.; Ahmad, F.; Babazadeh, D. FangFang, X.; Modarresi-Ghazani, F.; WenHua, L.; XiaoHui, Z. Chlorogenic acid (CGA): A pharmacological review and call for further research. Biomed. Pharmacother., 2018, 97, 67-74. doi: 10.1016/j.biopha.2017.10.064 PMID: 29080460Sikandar, S.; Dickenson, A.H. Visceral pain. Curr. Opin. Support. Palliat. Care, 2012, 6(1), 17-26. doi: 10.1097/SPC.0b013e32834f6ec9 PMID: 22246042Fukudo, S.; Kuwano, H.; Miwa, H. Management and pathophysiology of functional gastrointestinal disorders. Digestion, 2012, 85(2), 85-89. doi: 10.1159/000334652 PMID: 22269284Ritchie, J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut, 1973, 14(2), 125-132. doi: 10.1136/gut.14.2.125 PMID: 4696535Taki, M.; Oshima, T.; Li, M.; Sei, H.; Tozawa, K.; Tomita, T.; Fukui, H.; Watari, J.; Miwa, H. Duodenal low‐grade inflammation and expression of tight junction proteins in functional dyspepsia. Neurogastroenterol. Motil., 2019, 31(10), e13576. doi: 10.1111/nmo.13576 PMID: 30790378Cremon, C.; Carini, G.; Wang, B.; Vasina, V.; Cogliandro, R.F.; De Giorgio, R.; Stanghellini, V.; Grundy, D.; Tonini, M.; De Ponti, F.; Corinaldesi, R.; Barbara, G. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am. J. Gastroenterol., 2011, 106(7), 1290-1298. doi: 10.1038/ajg.2011.86 PMID: 21427712Barbara, G.; Cremon, C.; De Giorgio, R.; Dothel, G.; Zecchi, L.; Bellacosa, L.; Carini, G.; Stanghellini, V.; Corinaldesi, R. Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome. Curr. Gastroenterol. Rep., 2011, 13(4), 308-315. doi: 10.1007/s11894-011-0195-7 PMID: 21537962Akbar, A.; Walters, J.R.F.; Ghosh, S. Review article: visceral hypersensitivity in irritable bowel syndrome: Molecular mechanisms and therapeutic agents. Aliment. Pharmacol. Ther., 2009, 30(5), 423-435. doi: 10.1111/j.1365-2036.2009.04056.x PMID: 19493256Lee, K.N.; Lee, O.Y. Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. World J. Gastroenterol., 2014, 20(27), 8886-8897. PMID: 25083061Ceuleers, H.; Van Spaendonk, H.; Hanning, N.; Heirbaut, J.; Lambeir, A.M.; Joossens, J.; Augustyns, K.; De Man, J.G.; De Meester, I.; De Winter, B.Y. Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases. World J. Gastroenterol., 2016, 22(47), 10275-10286. doi: 10.3748/wjg.v22.i47.10275 PMID: 28058009Lackner, J.M.; Gudleski, G.D.; Thakur, E.R.; Stewart, T.J.; Iacobucci, G.J.; Spiegel, B.M.R. The impact of physical complaints, social environment, and psychological functioning on IBS patients’ health perceptions: looking beyond GI symptom severity. Am. J. Gastroenterol., 2014, 109(2), 224-233. doi: 10.1038/ajg.2013.410 PMID: 24419481Pradhan, K.; Thakur, D.; Sudhan, N. Therapeutic efficacy of Punica granatum and Cucurbita maxima against clinical cases of nematodiasis in calves. Indian J. Indigenous Med, 1993.Carroll, S.Y.; O’Mahony, S.M.; Grenham, S.; Cryan, J.F.; Hyland, N.P. Disodium cromoglycate reverses colonic visceral hypersensitivity and influences colonic ion transport in a stress-sensitive rat strain. PLoS One, 2013, 8(12), e84718. doi: 10.1371/journal.pone.0084718 PMID: 24367692Camilleri, M.; Boeckxstaens, G. Dietary and pharmacological treatment of abdominal pain in IBS. Gut, 2017, 66(5), 966-974. doi: 10.1136/gutjnl-2016-313425 PMID: 28232472Camilleri, M.; Ford, A. Pharmacotherapy for irritable bowel syndrome. J. Clin. Med., 2017, 6(11), 101. doi: 10.3390/jcm6110101 PMID: 29077050Nelson, A.D.; Camilleri, M.; Chirapongsathorn, S.; Vijayvargiya, P.; Valentin, N.; Shin, A.; Erwin, P.J.; Wang, Z.; Murad, M.H. Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis. Gut, 2017, 66(9), 1611-1622. doi: 10.1136/gutjnl-2016-311835 PMID: 27287486Stanisor, O.I.; van Diest, S.A.; Yu, Z.; Welting, O.; Bekkali, N.; Shi, J.; de Jonge, W.J.; Boeckxstaens, G.E.; van den Wijngaard, R.M. Stress-induced visceral hypersensitivity in maternally separated rats can be reversed by peripherally restricted histamine-1-receptor antagonists. PLoS One, 2013, 8(6), e66884. doi: 10.1371/journal.pone.0066884 PMID: 23776699Riediger, C.; Schuster, T.; Barlinn, K.; Maier, S.; Weitz, J.; Siepmann, T. Adverse effects of antidepressants for chronic pain: A systematic review and meta-analysis. Front. Neurol., 2017, 8(307), 307. doi: 10.3389/fneur.2017.00307 PMID: 28769859Balemans, D.; Boeckxstaens, G.E.; Talavera, K.; Wouters, M.M. Transient receptor potential ion channel function in sensory transduction and cellular signaling cascades underlying visceral hypersensitivity. Am. J. Physiol. Gastrointest. Liver Physiol., 2017, 312(6), G635-G648. doi: 10.1152/ajpgi.00401.2016 PMID: 28385695Chan, C.L.H.; Facer, P.; Davis, J.B.; Smith, G.D.; Egerton, J.; Bountra, C.; Williams, N.S.; Anand, P. Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency. Lancet, 2003, 361(9355), 385-391. doi: 10.1016/S0140-6736(03)12392-6 PMID: 12573376Chen, L.; Ilham, S.J.; Feng, B. Pharmacological approach for managing pain in irritable bowel syndrome: a review article. Anesth. Pain Med., 2017, 7(2), e42747. doi: 10.5812/aapm.42747 PMID: 28824858Annaházi, A.; Róka, R.; Rosztóczy, A.; Wittmann, T. Role of antispasmodics in the treatment of irritable bowel syndrome. World J. Gastroenterol., 2014, 20(20), 6031-6043. doi: 10.3748/wjg.v20.i20.6031 PMID: 24876726Fuentes, I.M.; Christianson, J.A. Ion channels, ion channel receptors, and visceral hypersensitivity in irritable bowel syndrome. Neurogastroenterol. Motil., 2016, 28(11), 1613-1618. doi: 10.1111/nmo.12979 PMID: 27781369Winston, JH.; Xu, GY.; Sarna, SK. Adrenergic stimulation mediates visceral hypersensitivity to colorectal distension following heterotypic chronic stress. Gastroenterology, 2010, 138(1), 294-304. doi: 10.1053/j.gastro.2009.09.054Iwata, Y.; Ando, K.; Taniguchi, K.; Koba, N.; Sugiura, A.; Sudo, M. Identification of a highly potent and selective CB2 agonist, RQ-00202730, for the treatment of irritable bowel syndrome. Bioorg. Med. Chem. Lett., 2015, 25(2), 236-240. doi: 10.1016/j.bmcl.2014.11.062 PMID: 25499880Kikuchi, A.; Ohashi, K.; Sugie, Y.; Sugimoto, H.; Omura, H. Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity. J. Pharmacol. Sci., 2008, 106(2), 219-224. doi: 10.1254/jphs.FP0071599 PMID: 18270474Castro, J.; Harrington, AM.; Hughes, PA.; Martin, CM.; Ge, P.; Shea, CM. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3′, 5′-monophosphate. Gastroenterology, 2013, 145(6), 1334-1346.Zong, Y.; Zhu, S.; Zhang, S.; Zheng, G.; Wiley, J.W.; Hong, S. Chronic stress and intestinal permeability: Lubiprostone regulates glucocorticoid receptor‐mediated changes in colon epithelial tight junction proteins, barrier function, and visceral pain in the rodent and human. Neurogastroenterol. Motil., 2019, 31(2), e13477. doi: 10.1111/nmo.13477 PMID: 30284340Roudsari, N.M.; Lashgari, N.A.; Momtaz, S.; Farzaei, M.H.; Marques, A.M.; Abdolghaffari, A.H. Natural polyphenols for the prevention of irritable bowel syndrome: molecular mechanisms and targets; a comprehensive review. Daru, 2019, 27(2), 755-780. doi: 10.1007/s40199-019-00284-1 PMID: 31273572Tan, N.; Gwee, K.A.; Tack, J.; Zhang, M.; Li, Y.; Chen, M.; Xiao, Y. Herbal medicine in the treatment of functional gastrointestinal disorders: A systematic review with meta‐analysis. J. Gastroenterol. Hepatol., 2020, 35(4), 544-556. doi: 10.1111/jgh.14905 PMID: 31674057Hawrelak, J.A.; Wohlmuth, H.; Pattinson, M.; Myers, S.P.; Goldenberg, J.Z.; Harnett, J.; Cooley, K.; Van De Venter, C.; Reid, R.; Whitten, D.L. Western herbal medicines in the treatment of irritable bowel syndrome: A systematic review and meta-analysis. Complement. Ther. Med., 2020, 48, 102233. doi: 10.1016/j.ctim.2019.102233 PMID: 31987249Vandenberghe, A.; Schol, J.; Van den Houte, K.; Masuy, I.; Carbone, F.; Tack, J. Current and emerging therapeutic options for the management of functional dyspepsia. Expert Opin. Pharmacother., 2020, 21(3), 365-376. doi: 10.1080/14656566.2019.1707805 PMID: 31899982Pountos, I.; Theodora Georgouli, ; Howard Bird, ; Giannoudis, P. Nonsteroidal anti-inflammatory drugs: prostaglandins, indications, and side effects. Int. J. Infereron Cytokine Mediator Res., 2011, 3, 19. doi: 10.2147/IJICMR.S10200Lazzaroni, M.; Bianchi Porro, G. Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations. Aliment. Pharmacol. Ther., 2004, 20(Suppl. 2), 48-58. doi: 10.1111/j.1365-2036.2004.02037.x PMID: 15335413Sostres, C.; Gargallo, C.J.; Lanas, A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res. Ther., 2013, 15(Suppl 3)(Suppl. 3), S3. doi: 10.1186/ar4175 PMID: 24267289Dolatabadi, F.; Abdolghaffari, A.H.; Farzaei, M.H.; Baeeri, M.; Ziarani, F.S.; Eslami, M.; Abdollahi, M.; Rahimi, R. The protective effect of melissa officinalis l. in visceral hypersensitivity in rat using 2 models of acid-induced colitis and stress-induced irritable bowel syndrome: A possible role of nitric oxide pathway. J. Neurogastroenterol. Motil., 2018, 24(3), 490-501. doi: 10.5056/jnm17035 PMID: 29879761Ribeiro, M.A.; Bernardo-Gil, M.G.; Esquível, M.M. Melissa officinalis, L.: study of antioxidant activity in supercritical residues. J. Supercrit. Fluids, 2001, 21(1), 51-60. doi: 10.1016/S0896-8446(01)00078-XMiraj, S.; Azizi, N.; Kiani, S. A review of chemical components and pharmacological effects of Melissa officinalis L. Pharm. Lett., 2016, 8(6), 229-237.Noguchi-Shinohara, M.; Ono, K.; Hamaguchi, T.; Iwasa, K.; Nagai, T.; Kobayashi, S.; Nakamura, H.; Yamada, M. Pharmacokinetics, safety and tolerability of melissa officinalis extract which contained rosmarinic acid in healthy individuals: A randomized controlled trial. PLoS One, 2015, 10(5), e0126422. doi: 10.1371/journal.pone.0126422 PMID: 25978046Alijaniha, F.; Naseri, M.; Afsharypuor, S.; Fallahi, F.; Noorbala, A.; Mosaddegh, M.; Faghihzadeh, S.; Sadrai, S. Heart palpitation relief with Melissa officinalis leaf extract: Double blind, randomized, placebo controlled trial of efficacy and safety. J. Ethnopharmacol., 2015, 164, 378-384. doi: 10.1016/j.jep.2015.02.007 PMID: 25680840Akhondzadeh, S.; Noroozian, M.; Mohammadi, M.; Ohadinia, S.; Jamshidi, A.H.; Khani, M. Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: A double blind, randomised, placebo controlled trial. J. Neurol. Neurosurg. Psychiatry, 2003, 74(7), 863-866. doi: 10.1136/jnnp.74.7.863 PMID: 12810768Shakeri, A.; Sahebkar, A.; Javadi, B. Melissa officinalis L. – A review of its traditional uses, phytochemistry and pharmacology. J. Ethnopharmacol., 2016, 188, 204-228. doi: 10.1016/j.jep.2016.05.010 PMID: 27167460Son, H.J.; Jung, K.; Park, Y.H.; Jeon, H.J.; Kang, M.; Ryu, K.H.; Pyo, S.S.; Eutamene, H.; Bueno, L.; Sun, W.S. Inhibitory effects of SKI3246, the rhizome extract of Atractylodes japonica, on visceral hypersensitivity in experimental irritable bowel syndrome rat models. Arch. Pharm. Res., 2015, 38(5), 642-649. doi: 10.1007/s12272-014-0454-x PMID: 25070763Park, J.J.; Chon, N.R.; Lee, Y.J.; Park, H. The effects of an extract of Atractylodes japonica rhizome, SKI3246 on gastrointestinal motility in guinea pigs. J. Neurogastroenterol. Motil., 2015, 21(3), 352-360. doi: 10.5056/jnm14112 PMID: 26130631Kim, Y.C.; Jun, M.; Jeong, W.S.; Chung, S.K. antioxidant properties of flavone C‐glycosides from atractylodes japonica leaves in human low‐density lipoprotein oxidation. J. Food Sci., 2005, 70(9), S575-S580. doi: 10.1111/j.1365-2621.2005.tb08331.xKim, J.H.; Lee, J.H.; Jeong, S.M.; Lee, B.H.; Yoon, I.S.; Lee, J.H.; Choi, S.H.; Nah, S.Y. Effect of ginseng saponins on a rat visceral hypersensitivity model. Biol. Pharm. Bull., 2005, 28(11), 2120-2124. doi: 10.1248/bpb.28.2120 PMID: 16272701Kim, J.; Nah, S. Effects of ginsenoside total saponins on experimental irritable bowel syndrome in rats. J. Ginseng Res., 2005, 29(2), 94-99. doi: 10.5142/JGR.2005.29.2.094Rocha, H.A.C.; Rocha, T.V.; Nóbrega, F.J.F.; Morais, L.C.S.; Diniz, M.F.F.M. Randomized controlled trial of Panax ginseng in patients with irritable bowel syndrome. Rev. Bras. Farmacogn., 2018, 28(2), 218-222. doi: 10.1016/j.bjp.2018.02.007Khanna, R.; MacDonald, J.K.; Levesque, B.G. Peppermint oil for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. J. Clin. Gastroenterol., 2014, 48(6), 505-512. doi: 10.1097/MCG.0b013e3182a88357 PMID: 24100754Galeotti, N.; Di Cesare Mannelli, L.; Mazzanti, G.; Bartolini, A.; Ghelardini, C. Menthol: A natural analgesic compound. Neurosci. Lett., 2002, 322(3), 145-148. doi: 10.1016/S0304-3940(01)02527-7 PMID: 11897159Liu, B.; Fan, L.; Balakrishna, S.; Sui, A.; Morris, J.B.; Jordt, S.E. TRPM8 is the principal mediator of menthol-induced analgesia of acute and inflammatory pain. Pain, 2013, 154(10), 2169-2177. doi: 10.1016/j.pain.2013.06.043 PMID: 23820004Harrington, A.M.; Hughes, P.A.; Martin, C.M.; Yang, J.; Castro, J.; Isaacs, N.J.; Blackshaw, A.L.; Brierley, S.M. A novel role for TRPM8 in visceral afferent function. Pain, 2011, 152(7), 1459-1468. doi: 10.1016/j.pain.2011.01.027 PMID: 21489690Rich, G.; Shah, A.; Koloski, N.; Funk, P.; Stracke, B.; Köhler, S.; Holtmann, G. A randomized placebo-controlled trial on the effects of Menthacarin, a proprietary peppermint- and caraway-oil-preparation, on symptoms and quality of life in patients with functional dyspepsia. Neurogastroenterol. Motil., 2017, 29(11), e13132. doi: 10.1111/nmo.13132 PMID: 28695660Botschuijver, S.; Welting, O.; Levin, E.; Maria-Ferreira, D.; Koch, E.; Montijn, R.C.; Seppen, J.; Hakvoort, T.B.M.; Schuren, F.H.J.; de Jonge, W.J.; van den Wijngaard, R.M. Reversal of visceral hypersensitivity in rat by Menthacarin ®, a proprietary combination of essential oils from peppermint and caraway, coincides with mycobiome modulation. Neurogastroenterol. Motil., 2018, 30(6), e13299. doi: 10.1111/nmo.13299 PMID: 29383802Yang, J.M.; Xian, Y.F.; Ip, P.S.P.; Wu, J.C.Y.; Lao, L.; Fong, H.H.S.; Sung, J.J.Y.; Berman, B.; Yeung, J.H.K.; Che, C.T. Schisandra chinensis reverses visceral hypersensitivity in a neonatal–maternal separated rat model. Phytomedicine, 2012, 19(5), 402-408. doi: 10.1016/j.phymed.2011.11.013 PMID: 22230486Amiri, M.; Navabi, J.; Shokoohinia, Y.; Heydarpour, F.; Bahrami, G.; Behbood, L.; Derakhshandeh, P.; Momtaz, S.; Farzaei, M.H. Efficacy and safety of a standardized extract from Achillea wilhelmsii C. Koch in patients with ulcerative colitis: A randomized double blind placebo-controlled clinical trial. Complement. Ther. Med., 2019, 45, 262-268. doi: 10.1016/j.ctim.2019.05.001 PMID: 31331572Lashgari, N.A.; Momeni Roudsari, N.; Khayatan, D.; Shayan, M.; Momtaz, S.; Roufogalis, B.D. Ginger and its constituents: Role in treatment of inflammatory bowel disease. Biofactors, 2021, 48(1), 7-21. PMID: 34882874Zhang, C.; Huang, Y.; Li, P.; Chen, X.; Liu, F.; Hou, Q. Ginger relieves intestinal hypersensitivity of diarrhea predominant irritable bowel syndrome by inhibiting proinflammatory reaction. BMC Complement Med Ther., 2020, 20(1), 272. doi: 10.1186/s12906-020-03059-3Simrén, M.; Törnblom, H.; Palsson, OS.; Van Oudenhove, L.; Whitehead, WE.; Tack, J. Cumulative effects of psychologic distress, visceral hypersensitivity, and abnormal transit on patient-reported outcomes in irritable bowel syndrome. Gastroenterology, 2019, 157(2), 391-402. doi: 10.1053/j.gastro.2019.04.019Shi, H.; Zhu, X.; Cui, Y.; Qin, Y.; Yang, L.; Deng, X. Analgesic activity of cynaropicrinon on post inflammatory irritable bowel syndrome visceral hypersensitivity in a rat model. Exp. Ther. Med., 2017, 14(5), 4476-4482. doi: 10.3892/etm.2017.5037 PMID: 29067122Rahimi, R.; Abdollahi, M. Herbal medicines for the management of irritable bowel syndrome: A comprehensive review. World J. Gastroenterol., 2012, 18(7), 589-600. doi: 10.3748/wjg.v18.i7.589 PMID: 22363129Abdollahi, M.; Esmaily, H.; Baeeri, M.; Asadi-Shahmirzadi, A.; Mozaffari, S.; Rahimi, R.; Sanei, Y.; Salehi-Surmaghi, M-H. Effects of Hypericum perforatum extract on rat irritable bowel syndrome. Pharmacogn. Mag., 2011, 7(27), 213-223. doi: 10.4103/0973-1296.84235 PMID: 21969792Brinkhaus, B.; Hentschel, C.; Keudell, C.V.; Schindler, G.; Lindner, M.; Stützer, H.; Kohnen, R.; Willich, S.N.; Lehmacher, W.; Hahn, E.G.G. Herbal medicine with curcuma and fumitory in the treatment of irritable bowel syndrome: A randomized, placebo-controlled, double-blind clinical trial. Scand. J. Gastroenterol., 2005, 40(8), 936-943. doi: 10.1080/00365520510023134 PMID: 16173134Cooke, C.; Carr, I.; Abrams, K.; Mayberry, J. Arrowroot as a treatment for diarrhoea in irritable bowel syndrome patients: a pilot study. Arq. Gastroenterol., 2000, 37(1), 20-24. doi: 10.1590/S0004-28032000000100005 PMID: 10962623Uezono, Y.; Miyano, K. Visceral hypersensitivity in functional dyspepsia (FD): Therapeutic approaches to FD based on suppression of visceral hypersensitivity. Functional Dyspepsia; Springer: Cham, 2018, pp. 167-177. doi: 10.1007/978-981-13-1074-4_15Liu, C.Y.; Müller, M.H.; Glatzle, J.; Weiser, D.; Kelber, O.; Enck, P.; Grundy, D.; Kreis, M.E. The herbal preparation STW 5 (IberogastR) desensitizes intestinal afferents in the rat small intestine1. Neurogastroenterol. Motil., 2004, 16(6), 759-764. doi: 10.1111/j.1365-2982.2004.00576.x PMID: 15601426Hong, S.W.; Chun, J.; Park, S.; Lee, H.J.; Im, J.P.; Kim, J.S. Aloe vera is effective and safe in short-term treatment of irritable bowel syndrome: a systematic review and meta-analysis. J. Neurogastroenterol. Motil., 2018, 24(4), 528-535. doi: 10.5056/jnm18077 PMID: 30153721Asadi-Shahmirzadi, A.; Mozaffari, S.; Sanei, Y.; Baeeri, M.; Hajiaghaee, R.; Monsef-Esfahani, H.R.; Abdollahi, M. Benefit of Aloe vera and Matricaria recutita mixture in rat irritable bowel syndrome: Combination of antioxidant and spasmolytic effects. Chin. J. Integr. Med., 2012, 1-9. doi: 10.1007/s11655-012-1027-9 PMID: 23263994Davis, K.; Philpott, S.; Kumar, D.; Mendall, M. Randomised double-blind placebo-controlled trial of aloe vera for irritable bowel syndrome. Int. J. Clin. Pract., 2006, 60(9), 1080-1086. doi: 10.1111/j.1742-1241.2006.00980.x PMID: 16749917Malik, Z.; Baik, D.; Schey, R. The role of cannabinoids in regulation of nausea and vomiting, and visceral pain. Curr. Gastroenterol. Rep., 2015, 17(2), 9. doi: 10.1007/s11894-015-0429-1 PMID: 25715910Bogale, K.; Raup-Konsavage, W.; Dalessio, S.; Vrana, K.; Coates, M.D. Cannabis and cannabis derivatives for abdominal pain management in inflammatory bowel disease. Med. Cannabis Cannabinoids, 2021, 4(2), 97-106. doi: 10.1159/000517425 PMID: 35224429Ng, Q.X.; Koh, S.S.H.; Chan, H.W.; Ho, C.Y.X. Clinical use of curcumin in depression: a meta-analysis. J. Am. Med. Dir. Assoc., 2017, 18(6), 503-508. doi: 10.1016/j.jamda.2016.12.071 PMID: 28236605Aggarwal, B.B.; Harikumar, K.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell Biol., 2009, 41(1), 40-59. doi: 10.1016/j.biocel.2008.06.010 PMID: 18662800Ak, T.; Gülçin, İ. Antioxidant and radical scavenging properties of curcumin. Chem. Biol. Interact., 2008, 174(1), 27-37. doi: 10.1016/j.cbi.2008.05.003 PMID: 18547552Dong, S.; Zeng, Q.; Mitchell, E.S.; Xiu, J.; Duan, Y.; Li, C.; Tiwari, J.K.; Hu, Y.; Cao, X.; Zhao, Z. Curcumin enhances neurogenesis and cognition in aged rats: implications for transcriptional interactions related to growth and synaptic plasticity. PLoS One, 2012, 7(2), e31211. doi: 10.1371/journal.pone.0031211 PMID: 22359574Ammon, H.; Wahl, M. Pharmacology of Curcuma longa. Planta Med., 1991, 57(1), 1-7. doi: 10.1055/s-2006-960004 PMID: 2062949Yu, Y.; Wu, S.; Li, J.; Wang, R.; Xie, X.; Yu, X.; Pan, J.; Xu, Y.; Zheng, L. The effect of curcumin on the brain-gut axis in rat model of irritable bowel syndrome: involvement of 5-HT-dependent signaling. Metab. Brain Dis., 2015, 30(1), 47-55. doi: 10.1007/s11011-014-9554-z PMID: 24807589Zhi, L.; Dong, L.; Kong, D.; Sun, B.; Sun, Q.; Grundy, D.; Zhang, G.; Rong, W. Curcumin acts via transient receptor potential vanilloid-1 receptors to inhibit gut nociception and reverses visceral hyperalgesia. Neurogastroenterol. Motil., 2013, 25(6), e429-e440. doi: 10.1111/nmo.12145 PMID: 23638900Qin, S.; Huang, L.; Gong, J.; Shen, S.; Huang, J.; Ren, H.; Hu, H. Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials. Nutr. J., 2017, 16(1), 68. doi: 10.1186/s12937-017-0293-y PMID: 29020971Chung, J.H. Metabolic benefits of inhibiting cAMP-PDEs with resveratrol. Adipocyte, 2012, 1(4), 256-258. doi: 10.4161/adip.21158 PMID: 23700542Sale, S.; Verschoyle, R.D.; Boocock, D.; Jones, D.J.L.; Wilsher, N.; Ruparelia, K.C.; Potter, G.A.; Farmer, P.B.; Steward, W.P.; Gescher, A.J. Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4′-tetramethoxystilbene. Br. J. Cancer, 2004, 90(3), 736-744. doi: 10.1038/sj.bjc.6601568 PMID: 14760392Frozza, R.L.; Bernardi, A.; Paese, K.; Hoppe, J.B.; Silva, T.; Battastini, A.M.O.; Pohlmann, A.R.; Guterres, S.S.; Salbego, C. Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats. J. Biomed. Nanotechnol., 2010, 6(6), 694-703. doi: 10.1166/jbn.2010.1161 PMID: 21361135Xu, Y.; Cui, S.Y.; Ma, Q.; Shi, J.; Yu, Y.; Li, J.X.; Zheng, L.; Zhang, Y.; Si, J.M.; Yu, Y.C. Trans-resveratrol ameliorates stress-induced irritable bowel syndrome-like behaviors by regulation of brain-gut axis. Front. Pharmacol., 2018, 9, 631. doi: 10.3389/fphar.2018.00631 PMID: 29962949Lu, Y.; Xu, H.; Han, Y.; Zhang, Y. Analgesic effect of resveratrol on colitis-induced visceral pain via inhibition of TRAF6/NF-κB signaling pathway in the spinal cord. Brain Res., 2019, 1724, 146464. doi: 10.1016/j.brainres.2019.146464 PMID: 31536729Parasuraman, S.; Anand David, A.V.; Arulmoli, R. Overviews of biological importance of quercetin: A bioactive flavonoid. Pharmacogn. Rev., 2016, 10(20), 84-89. doi: 10.4103/0973-7847.194044 PMID: 28082789Espley, R.V.; Butts, C.A.; Laing, W.A.; Martell, S.; Smith, H.; McGhie, T.K.; Zhang, J.; Paturi, G.; Hedderley, D.; Bovy, A.; Schouten, H.J.; Putterill, J.; Allan, A.C.; Hellens, R.P. Dietary flavonoids from modified apple reduce inflammation markers and modulate gut microbiota in mice. J. Nutr., 2014, 144(2), 146-154. doi: 10.3945/jn.113.182659 PMID: 24353343Yano, J.M.; Yu, K.; Donaldson, G.P.; Shastri, G.G.; Ann, P.; Ma, L.; Nagler, C.R.; Ismagilov, R.F.; Mazmanian, S.K.; Hsiao, E.Y. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell, 2015, 161(2), 264-276. doi: 10.1016/j.cell.2015.02.047 PMID: 25860609Qin, H.Y.; Zang, K.H.; Zuo, X.; Wu, X.A.; Bian, Z.X. Quercetin attenuates visceral hypersensitivity and 5-Hydroxytryptamine availability in Postinflammatory irritable bowel syndrome rats: role of Enterochromaffin cells in the Colon. J. Med. Food, 2019, 22(7), 663-671. doi: 10.1089/jmf.2018.4264 PMID: 30920336Andres, S.; Pevny, S.; Ziegenhagen, R.; Bakhiya, N.; Schäfer, B.; Hirsch-Ernst, K.I.; Lampen, A. Safety aspects of the use of quercetin as a dietary supplement. Mol. Nutr. Food Res., 2018, 62(1), 1700447. doi: 10.1002/mnfr.201700447 PMID: 29127724Mohammadinejad, R.; Ahmadi, Z.; Tavakol, S.; Ashrafizadeh, M. Berberine as a potential autophagy modulator. J. Cell. Physiol., 2019, 234(9), 14914-14926. doi: 10.1002/jcp.28325 PMID: 30770555Yu, Z.C.; Cen, Y.X.; Wu, B.H.; Wei, C.; Xiong, F.; Li, D.F.; Liu, T.T.; Luo, M.H.; Guo, L.L.; Li, Y.X.; Wang, L.S.; Wang, J.Y.; Yao, J. Berberine prevents stress-induced gut inflammation and visceral hypersensitivity and reduces intestinal motility in rats. World J. Gastroenterol., 2019, 25(29), 3956-3971. doi: 10.3748/wjg.v25.i29.3956 PMID: 31413530Zhang, X.; Li, Z.; Leung, W.; Liu, L.; Xu, H.; Bian, Z. The analgesic effect of paeoniflorin on neonatal maternal separation-induced visceral hyperalgesia in rats. J. Pain, 2008, 9(6), 497-505. doi: 10.1016/j.jpain.2007.12.009 PMID: 18387856Zhang, X.J.; Chen, H.L.; Li, Z.; Zhang, H.Q.; Xu, H.X.; Sung, J.J.Y.; Bian, Z.X. Analgesic effect of paeoniflorin in rats with neonatal maternal separation-induced visceral hyperalgesia is mediated through adenosine A1 receptor by inhibiting the extracellular signal-regulated protein kinase (ERK) pathway. Pharmacol. Biochem. Behav., 2009, 94(1), 88-97. doi: 10.1016/j.pbb.2009.07.013 PMID: 19664651Chang, X.; Zhao, L.; Wang, J.; Lu, X.; Zhang, S. Sini-san improves duodenal tight junction integrity in a rat model of functional dyspepsia. BMC Complement. Altern. Med., 2017, 17(1), 432. doi: 10.1186/s12906-017-1938-2 PMID: 28854971Cai, L.; Jiejie, L.; Hu, Y.; Chen, W.; Wei, L.; He, Q. A efficacy and safety of modified sini san for treating poststroke depression: A meta-analysis of randomized controlled trials. Explore (NY), 2020. PMID: 32527684Moussa, L.; Bézirard, V.; Salvador-Cartier, C.; Bacquié, V.; Houdeau, E.; Théodorou, V. A new soy germ fermented ingredient displays estrogenic and protease inhibitor activities able to prevent irritable bowel syndrome-like symptoms in stressed female rats. Clin. Nutr., 2013, 32(1), 51-58. doi: 10.1016/j.clnu.2012.05.021 PMID: 22727545Lee, T.H.; Choi, J.J.; Kim, D.H.; Choi, S.; Lee, K.R.; Son, M.; Jin, M. Gastroprokinetic effects of DA-9701, a new prokinetic agent formulated with Pharbitis Semen and Corydalis Tuber. Phytomedicine, 2008, 15(10), 836-843. doi: 10.1016/j.phymed.2008.02.019 PMID: 18490147Kim, E.R.; Min, B.H.; Lee, T.H.; Son, M.; Rhee, P.L. Effect of DA-9701 on colorectal distension-induced visceral hypersensitivity in a rat model. Gut Liver, 2014, 8(4), 388-393. doi: 10.5009/gnl.2014.8.4.388 PMID: 25071903Lee, S.P.; Lee, K.N.; Lee, O.Y.; Lee, H.L.; Jun, D.W.; Yoon, B.C.; Choi, H.S.; Hwang, S.J.; Lee, S.E. Effects of DA-9701, a novel prokinetic agent, on phosphorylated extracellular signal-regulated kinase expression in the dorsal root ganglion and spinal cord induced by colorectal distension in rats. Gut Liver, 2014, 8(2), 140-147. doi: 10.5009/gnl.2014.8.2.140 PMID: 24672654Gershon, M.D.; Tack, J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology, 2007, 132(1), 397-414. doi: 10.1053/j.gastro.2006.11.002 PMID: 17241888Madisch, A.; Melderis, H.; Mayr, G.; Sassin, I.; Hotz, J. A plant extract and its modified preparation in functional dyspepsia. Results of a double-blind placebo controlled comparative study Z. Gastroenterol., 2001, 39(7), 511-517. doi: 10.1055/s-2001-16142 PMID: 11505331Müller, M.H.; Liu, C.Y.; Glatzle, J.; Weiser, D.; Kelber, O.; Enck, P.; Grundy, D.; Kreis, M.E. STW 5 (Iberogast®) reduces afferent sensitivity in the rat small intestine. Phytomedicine, 2006, 13(Suppl. 5), 100-106. doi: 10.1016/j.phymed.2006.03.014 PMID: 16713220Malfertheiner, P. STW 5 (Iberogast) therapy in gastrointestinal functional disorders. Dig. Dis., 2017, 35(S1)(Suppl. 1), 25-29. doi: 10.1159/000485410 PMID: 29421817Fan, H.; Qiu, M-Y.; Mei, J-J.; Shen, G-X.; Liu, S-L.; Chen, R. Effects of four regulating-intestine prescriptions on pathology and ultrastructure of colon tissue in rats with ulcerative colitis. World J. Gastroenterol., 2005, 11(31), 4800-4806. doi: 10.3748/wjg.v11.i31.4800 PMID: 16097047Bian, Z.; Wu, T.; Liu, L.; Miao, J.; Wong, H.; Song, L.; Sung, J.J.Y. Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review. J. Altern. Complement. Med., 2006, 12(4), 401-407. doi: 10.1089/acm.2006.12.401 PMID: 16722791Hu, X.G.; Xu, D.; Zhao, Y.; Yang, X.B.; Meng, J.; Shen, H.; Guo, J. The alleviating pain effect of aqueous extract from tong-xie-yao-fang, on experimental visceral hypersensitivity and its mechanism. Biol. Pharm. Bull., 2009, 32(6), 1075-1079. doi: 10.1248/bpb.32.1075 PMID: 19483318Pan, F.; Zhang, T.; Zhang, Y.; Xu, J.; Chen, F. Effect of Tongxie Yaofang (痛泻要方) Granule in treating diarrhea-predominate irritable bowel syndrome. Chin. J. Integr. Med., 2009, 15(3), 216-219. doi: 10.1007/s11655-009-0216-7 PMID: 19568715Yin, Y.; Zhong, L.; Wang, J.W.; Zhao, X.Y.; Zhao, W.J.; Kuang, H.X. Tong Xie Yao Fang relieves irritable bowel syndrome in rats via mechanisms involving regulation of 5-hydroxytryptamine and substance P. World J. Gastroenterol., 2015, 21(15), 4536-4546. doi: 10.3748/wjg.v21.i15.4536 PMID: 25914462Bian, Z-X.; Zhang, M.; Han, Q-B.; Xu, H-X.; Sung, J.J. Analgesic effects of JCM-16021 on neonatal maternal separation-induced visceral pain in rats. World J. Gastroenterol., 2010, 16(7), 837-845. PMID: 20143462Huang, X; Zeng, B; Zhou, F; Wang, R; Zeng, H. Studies on Quality Standard for Kangtai Capsule. 2000(06). Trad Chin Drug Res Clinic Pharmacol, 2000, 6Chen, Y.L.; Huang, X.Q.; Xu, S.J.; Liao, J.B.; Wang, R.J.; Lu, X.F.; Xie, Y.L.; Zhou, F.S.; Su, Z.R.; Lai, X.P. Relieving visceral hyperalgesia effect of Kangtai capsule and its potential mechanisms via modulating the 5-HT and NO level in vivo. Phytomedicine, 2013, 20(3-4), 249-257. doi: 10.1016/j.phymed.2012.09.027 PMID: 23141427Mertz, H.; Naliboff, B.; Munakata, J.; Niazi, N.; Mayer, E.A. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology, 1995, 109(1), 40-52. doi: 10.1016/0016-5085(95)90267-8 PMID: 7797041Rivkin, A. Tegaserod maleate in the treatment of irritable bowel syndrome: A clinical review. Clin. Ther., 2003, 25(7), 1952-1974. doi: 10.1016/S0149-2918(03)80198-4 PMID: 12946544Sikander, A.; Rana, S.V.; Prasad, K.K. Role of serotonin in gastrointestinal motility and irritable bowel syndrome. Clin. Chim. Acta, 2009, 403(1-2), 47-55. doi: 10.1016/j.cca.2009.01.028 PMID: 19361459Farmer, A.D.; Aziz, Q. Visceral pain hypersensitivity in functional gastrointestinal disorders. Br. Med. Bull., 2009, 91(1), 123-136. doi: 10.1093/bmb/ldp026 PMID: 19620136Bortolotti, M.; Porta, S. Effect of red pepper on symptoms of irritable bowel syndrome: preliminary study. Dig. Dis. Sci., 2011, 56(11), 3288-3295. doi: 10.1007/s10620-011-1740-9 PMID: 21573941Tatsuta, M.; Iishi, H. Effect of treatment with Liu-Jun-Zi-Tang (TJ-43) on gastric emptying and gastrointestinal symptoms in dyspeptic patients. Aliment. Pharmacol. Ther., 1993, 7(4), 459-462. doi: 10.1111/j.1365-2036.1993.tb00120.x PMID: 8218760Shiratori, M.; Shoji, T.; Kanazawa, M.; Hongo, M.; Fukudo, S. Effect of rikkunshito on gastric sensorimotor function under distention. Neurogastroenterol. Motil., 2011, 23(4), 323-e156. doi: 10.1111/j.1365-2982.2010.01648.x PMID: 21175995Liu, J.; Kou, F.; Tan, X.; Dai, Y.; Xie, C. Li, X Hewei Jiangni granule alleviates visceral hypersensitivity in a rat model of non-erosive reflux disease via transient receptor potential channel signaling. J Trad Chin Med Sci, 2020, 7(2), 162-170. doi: 10.1016/j.jtcms.2020.05.002Zhang, S.; Zhao, L.; Wang, H.; Wang, C.; Huang, S.; Shen, H.; Wei, W.; Tao, L.; Zhou, T. Efficacy of modified LiuJunZi decoction on functional dyspepsia of spleen-deficiency and qi-stagnation syndrome: A randomized controlled trial. BMC Complement. Altern. Med., 2013, 13(1), 54. doi: 10.1186/1472-6882-13-54 PMID: 23453018Wang, X.; Wang, B.; Zhou, T. The study on the effects of Jianpi Liqi Decoction on rats with functional dyspepsia and its mechanism; Chin J Integr Tradition West Med Digest, 2012, pp. 297-300.Bellono, N.W.; Bayrer, J.R.; Leitch, D.B.; Castro, J.; Zhang, C.; O’Donnell, T.A. Enterochromaffin cells are gut chemosensors that couple to sensory neural pathways. Cell, 2017, 170(1), 185-198. doi: 10.1016/j.cell.2017.05.034Zhao, J.; Zhao, L.; Zhang, S.; Zhu, C. Modified Liu-Jun-Zi decoction alleviates visceral hypersensitivity in functional dyspepsia by regulating EC cell-5HT3r signaling in duodenum. J. Ethnopharmacol., 2020, 250, 112468. doi: 10.1016/j.jep.2019.112468 PMID: 31836517Moazzam, S.W.; Mobeen, A.; Siddiqui, M.A. Efficacy of Jawarish Shahi a herbal formulation in irritable bowel syndrome: An open-labeled single-arm clinical trial. J. Tradit. Complement. Med., 2022, 12(6), 529-535. doi: 10.1016/j.jtcme.2022.04.004 PMID: 36325243Mobeen, A.; Moazzam, S.W. Jawarish Shahi: A special dosage form of herbal formulations for functional gastrointestinal disorders in Unani medicine- A comprehensive review. J. Ethnopharmacol., 2022, 293, 115319. doi: 10.1016/j.jep.2022.115319 PMID: 35490900